Can a targeted pill plus chemo shrink lung tumors before surgery?

NCT ID NCT05430802

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether giving the targeted drug furmonertinib along with standard chemotherapy before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II to IIIB). Participants take furmonertinib daily for 9 weeks plus three cycles of cisplatin and pemetrexed, then undergo surgery. The study aims to see how many patients respond to this pre-surgery treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
furmonertinib combined with cisplatin and pemetrexed
What this could lead to
If successful, this approach could shrink tumors before surgery, potentially improving outcomes for people with EGFR-mutated lung cancer.
What could go wrong
This is an early-phase, single-arm trial with only 40 participants. It may not prove better than standard treatment, and the drug combination carries risks like chemotherapy side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * With written informed consent before any study procedure * Histology or cytology diagnose of non-small cell lung cancer within 60 days * Stage IIA-IIIB (T3N2M0 only), with resectable lesion(s) by radiology * EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations) * Without prior anti-tumor treatment * With at least one measurable lesions * ECOG performance status 0-1 * Using adequate and effective contraception, women should refrain from breastfeeding and have a negative pregnancy test prior to the first administration of the study drug if within during child-bearing age Exclusion Criteria: * EGFR Exon 20 insertions positive * Mixed with small cell cancer, or other mixed types of lung cancer * Any prior anti-tumor treatment * Major surgery within 4 weeks before enrollment * Women with pregnancy or breastfeeding * Use of strong CYP3A4 inhibitors within 7 days or strong CYP3A4 inducers within 21 days before enrollment; use of traditional Chinese medicine with anti-tumor effect within 21 days before enrollment * With history of other malignancy except for radical resected tumors without recurrence for 5 years or more * With severe or uncontrolled systemic disease such as uncontrolled hypertention, diabetes mellitus, chronic heart failure, unstable angina, myocardial infarction within 1 year, active hemorrhage, active HBV/HCV/HIV or other infections requiring infusion treatment * Severe gastrointestinal diseases which may affect the intake and absorption of study drug * Prolongation of ECG QTc or with relative risk factors * History of interstitial lung disease or with relative risk factors * Inadequate organ function of hematology, liver and kidney * Allergic to study drugs or any component * Poor adherence or other situation judged by investigator * Patients who had participated other clinical studies of tumors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tangdu Hospital

    Xi'an, Shannxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.